Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

BMC Cancer

Table 1 Mutational status of PIK3CA, PTEN, NRAS and BRAF genes in New Zealand Melanoma (NZM) cell lines used for the study

Cell lines	PTENstatus	PIK3CAstatus	NRASstatus	BRAFstatus
NZM6	Exon3 deletion			V600E
NZM34	Exon 5 frameshift mutation			V600E
NZM43	Exon 1 frameshift mutation			V600K
NZM30	No identified mutation in exon 2-9*			V600E
NZM40		H1047R	Q61H
NZM46		H1047R	Q61H
NZM52		H1047R		V600E
NZM10			Q61H
NZM15			Q61H
NZM42			Q61H
NZM3				V600E
NZM12				V600E

*In NZM30, PTEN exon 1 sequencing failed after multiple attempts. The absence of PTEN protein in NZM30 (Figure 2) could be due to a large deletion in exon 1 or epigenetic changes

ISSN: 1471-2407